Product Code: TMRGL85240
TMR's report on the global anti-radiation drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global anti-radiation drugs market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global anti-radiation drugs market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the anti-radiation drugs market.
The report delves into the competitive landscape of the global anti-radiation drugs market. Key players operating in the global anti-radiation drugs market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global anti-radiation drugs market profiled in this report.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Anti-radiation Drugs Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Definition
- 4.1.2. Industry Evolution/Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Anti-radiation Drugs Market Analysis and Forecast, 2017-2031
5. Key Insights
- 5.1. Pipeline Analysis
- 5.2. Key Industry Events (Partnership, Investment, Merger & Acquisition, etc.)
- 5.3. Insights on Radiation Pills
- 5.4. Regulatory Scenario, by Key Region/ Country
- 5.5. COVID-19 Impact Analysis
6. Global Anti-radiation Drugs Market Analysis and Forecast, by Compound
- 6.1. Introduction & Definition
- 6.2. Market Value Forecast, by Compound, 2017-2031
- 6.2.1. Potassium Iodide (KI)
- 6.2.2. Prussian Blue
- 6.2.3. DTPA (Diethylenetriamine Pentaacetate)
- 6.2.4. Others
- 6.3. Market Attractiveness, by Compound
7. Global Anti-radiation Drugs Market Analysis and Forecast, by Application
- 7.1. Introduction & Definition
- 7.2. Market Value Forecast, by Application, 2017-2031
- 7.2.1. Acute Radiation Syndrome (ARS)
- 7.2.2. Cancer Treatment
- 7.2.3. Radiation Exposure
- 7.2.4. Others
- 7.3. Market Attractiveness Analysis, by Application
8. Global Anti-radiation Drugs Market Analysis and Forecast, by Distribution Channel
- 8.1. Introduction & Definition
- 8.2. Market Value Forecast, by Distribution Channel, 2017-2031
- 8.2.1. Hospital Pharmacies
- 8.2.2. Retail Pharmacies
- 8.2.3. Others
- 8.3. Market Attractiveness Analysis, by Distribution Channel
9. Global Anti-radiation Drugs Market Analysis and Forecast, by Region
- 9.1. Key Findings
- 9.2. Market Value Forecast, by Region
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
- 9.3. Market Attractiveness Analysis, by Region
10. North America Anti-radiation Drugs Market Analysis and Forecast
- 10.1. Introduction
- 10.2. Market Value Forecast, by Compound, 2017-2031
- 10.2.1. Potassium Iodide (KI)
- 10.2.2. Prussian Blue
- 10.2.3. DTPA (Diethylenetriamine Pentaacetate)
- 10.2.4. Others
- 10.3. Market Value Forecast, by Application, 2017-2031
- 10.3.1. Acute Radiation Syndrome (ARS)
- 10.3.2. Cancer Treatment
- 10.3.3. Radiation Exposure
- 10.3.4. Others
- 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
- 10.4.1. Hospital Pharmacies
- 10.4.2. Retail Pharmacies
- 10.4.3. Others
- 10.5. Market Value Forecast, by Country, 2017-2031
- 10.5.1. U.S.
- 10.5.2. Canada
- 10.6. Market Attractiveness Analysis
- 10.6.1. By Compound
- 10.6.2. By Application
- 10.6.3. By Distribution Channel
- 10.6.4. By Country
11. Europe Anti-radiation Drugs Market Analysis and Forecast
- 11.1. Introduction
- 11.2. Market Value Forecast, by Compound, 2017-2031
- 11.2.1. Potassium Iodide (KI)
- 11.2.2. Prussian Blue
- 11.2.3. DTPA (Diethylenetriamine Pentaacetate)
- 11.2.4. Others
- 11.3. Market Value Forecast, by Application, 2017-2031
- 11.3.1. Acute Radiation Syndrome (ARS)
- 11.3.2. Cancer Treatment
- 11.3.3. Radiation Exposure
- 11.3.4. Others
- 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
- 11.4.1. Hospital Pharmacies
- 11.4.2. Retail Pharmacies
- 11.4.3. Others
- 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.5.1. Germany
- 11.5.2. U.K.
- 11.5.3. France
- 11.5.4. Spain
- 11.5.5. Italy
- 11.5.6. Rest of Europe
- 11.6. Market Attractiveness Analysis
- 11.6.1. By Compound
- 11.6.2. By Application
- 11.6.3. By Distribution Channel
- 11.6.4. By Country/Sub-region
12. Asia Pacific Anti-radiation Drugs Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Market Value Forecast, by Compound, 2017-2031
- 12.2.1. Potassium Iodide (KI)
- 12.2.2. Prussian Blue
- 12.2.3. DTPA (Diethylenetriamine Pentaacetate)
- 12.2.4. Others
- 12.3. Market Value Forecast, by Application, 2017-2031
- 12.3.1. Acute Radiation Syndrome (ARS)
- 12.3.2. Cancer Treatment
- 12.3.3. Radiation Exposure
- 12.3.4. Others
- 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
- 12.4.1. Hospital Pharmacies
- 12.4.2. Retail Pharmacies
- 12.4.3. Others
- 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.5.1. China
- 12.5.2. Japan
- 12.5.3. India
- 12.5.4. Australia & New Zealand
- 12.5.5. Rest of Asia Pacific
- 12.6. Market Attractiveness Analysis
- 12.6.1. By Compound
- 12.6.2. By Application
- 12.6.3. By Distribution Channel
- 12.6.4. By Country/Sub-region
13. Latin America Anti-radiation Drugs Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Market Value Forecast, by Compound, 2017-2031
- 13.2.1. Potassium Iodide (KI)
- 13.2.2. Prussian Blue
- 13.2.3. DTPA (Diethylenetriamine Pentaacetate)
- 13.2.4. Others
- 13.3. Market Value Forecast, by Application, 2017-2031
- 13.3.1. Acute Radiation Syndrome (ARS)
- 13.3.2. Cancer Treatment
- 13.3.3. Radiation Exposure
- 13.3.4. Others
- 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
- 13.4.1. Hospital Pharmacies
- 13.4.2. Retail Pharmacies
- 13.4.3. Others
- 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.5.1. Brazil
- 13.5.2. Mexico
- 13.5.3. Rest of Latin America
- 13.6. Market Attractiveness Analysis
- 13.6.1. By Compound
- 13.6.2. By Application
- 13.6.3. By Distribution Channel
- 13.6.4. By Country/Sub-region
14. Middle East & Africa Anti-radiation Drugs Market Analysis and Forecast
- 14.1. Introduction
- 14.2. Market Value Forecast, by Compound, 2017-2031
- 14.2.1. Potassium Iodide (KI)
- 14.2.2. Prussian Blue
- 14.2.3. DTPA (Diethylenetriamine Pentaacetate)
- 14.2.4. Others
- 14.3. Market Value Forecast, by Application, 2017-2031
- 14.3.1. Acute Radiation Syndrome (ARS)
- 14.3.2. Cancer Treatment
- 14.3.3. Radiation Exposure
- 14.3.4. Others
- 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
- 14.4.1. Hospital Pharmacies
- 14.4.2. Retail Pharmacies
- 14.4.3. Others
- 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.5.1. GCC Countries
- 14.5.2. South Africa
- 14.5.3. Rest of Middle East & Africa
- 14.6. Market Attractiveness Analysis
- 14.6.1. By Compound
- 14.6.2. By Application
- 14.6.3. By Distribution Channel
- 14.6.4. By Country/Sub-region
15. Competition Landscape
- 15.1. Market Player - Competitive Matrix (by tier and size of companies)
- 15.2. Market Share Analysis, by Company (2021)
- 15.3. Company Profiles
- 15.3.1. Amgen Inc.
- 15.3.1.1. Company Overview
- 15.3.1.2. Compound Portfolio
- 15.3.1.3. SWOT Analysis
- 15.3.1.4. Financial Overview
- 15.3.1.5. Strategic Overview
- 15.3.2. Anbex Inc.
- 15.3.2.1. Company Overview
- 15.3.2.2. Compound Portfolio
- 15.3.2.3. SWOT Analysis
- 15.3.2.4. Financial Overview
- 15.3.2.5. Strategic Overview
- 15.3.3. Arco Pharmaceuticals LLC
- 15.3.3.1. Company Overview
- 15.3.3.2. Compound Portfolio
- 15.3.3.3. SWOT Analysis
- 15.3.3.4. Financial Overview
- 15.3.4. BTG International Inc.
- 15.3.4.1. Company Overview
- 15.3.4.2. Compound Portfolio
- 15.3.4.3. SWOT Analysis
- 15.3.4.4. Financial Overview
- 15.3.4.5. Strategic Overview
- 15.3.5. Cellphire, Inc.
- 15.3.5.1. Company Overview
- 15.3.5.2. Compound Portfolio
- 15.3.5.3. SWOT Analysis
- 15.3.5.4. Financial Overview
- 15.3.5.5. Strategic Overview
- 15.3.6. Chrysalis BioTherapeutics, Inc.
- 15.3.6.1. Company Overview
- 15.3.6.2. Compound Portfolio
- 15.3.6.3. SWOT Analysis
- 15.3.7. Darnitsa
- 15.3.7.1. Company Overview
- 15.3.7.2. Compound Portfolio
- 15.3.7.3. SWOT Analysis
- 15.3.7.4. Strategic Overview
- 15.3.8. Enzychem Lifesciences Corporation
- 15.3.8.1. Company Overview
- 15.3.8.2. Compound Portfolio
- 15.3.8.3. SWOT Analysis
- 15.3.8.4. Strategic Overview
- 15.3.9. Humanetics Corporation
- 15.3.9.1. Company Overview
- 15.3.9.2. Compound Portfolio
- 15.3.9.3. SWOT Analysis
- 15.3.9.4. Financial Overview
- 15.3.9.5. Strategic Overview
- 15.3.10. Mission Pharmacal Company
- 15.3.10.1. Company Overview
- 15.3.10.2. Compound Portfolio
- 15.3.10.3. SWOT Analysis
- 15.3.10.4. Financial Overview
- 15.3.10.5. Strategic Overview
- 15.3.11. Myelo Therapeutics GmbH
- 15.3.11.1. Company Overview
- 15.3.11.2. Compound Portfolio
- 15.3.11.3. SWOT Analysis
- 15.3.11.4. Financial Overview
- 15.3.11.5. Strategic Overview
- 15.3.12. Partner Therapeutics
- 15.3.12.1. Company Overview
- 15.3.12.2. Compound Portfolio
- 15.3.12.3. SWOT Analysis
- 15.3.12.4. Financial Overview
- 15.3.12.5. Strategic Overview
- 15.3.13. Pluri Inc.
- 15.3.13.1. Company Overview
- 15.3.13.2. Compound Portfolio
- 15.3.13.3. SWOT Analysis
- 15.3.13.4. Financial Overview
- 15.3.13.5. Strategic Overview
- 15.3.14. Other Players
- 15.3.14.1. Company Overview
- 15.3.14.2. Compound Portfolio
- 15.3.14.3. SWOT Analysis
- 15.3.14.4. Financial Overview
- 15.3.14.5. Strategic Overview